News
OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer
TAIPEI, TAIWAN, July 22/ — OBI Pharma, Inc., a Taiwan biotech company (GreTai 4174:TT), announced that it has completed patient enrollment in its Phase 2/3 …
OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award
The Republic of China Venture Capital Association hosted its “Venture Capital Star” event and award night on January 15, 2014, and OBI Pharma, Inc. was …
OBI Pharma Announces NT$ 1.5 Billion Capital Infusion
OBI Pharma, Inc. (GreTai Securities Market: 4174), announced a new round of financing amounting to NT$ 1.5 billion has been completed. This signals the beginning …
OBI Pharma Wins the “Greatest Potential Award” at the 2013 Outstanding Biotech Awards
18 July 2013 – ROC President Ma Ying-jeou attended 2013 BIO Taiwan Opening Ceremony and presented the “Company with the Greatest Potential Award” to OBI …
OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.
Taipei, Taiwan – 7 February 2013 – OBI Pharma, Inc. (GreTai Securities Market Code 4174) held its first extraordinary shareholders’ meeting of the year on …